Publications by authors named "Yogesh Rathore"

Breast cancer is the most common cancer in women globally, imposing a significant burden on global public health due to high death rates. Data from the World Health Organization show an alarming annual incidence of nearly 2.3 million new cases, drawing the attention of patients, healthcare professionals, and governments alike.

View Article and Find Full Text PDF

Purpose: A monoclonal antibody, trastuzumab, is used for immunotherapy for HER2-expressing breast cancers. Large-sized antibodies demonstrate hepatobiliary clearance and slower pharmacokinetics. A trastuzumab fragment (Fab; 45 kDa) has been generated for theranostic use.

View Article and Find Full Text PDF

Selective-intra-arterial radionuclide therapy (SIRT) using radiolabeled microspheres are being widely employed for the delivery of therapeutic radioisotope to liver cancers by exploiting the dual blood supply to liver. It delivers the therapeutic radiations to tumor and spares the healthy liver. Several radiolabeled microspheres formulations, labelled with Y, are commercially available.

View Article and Find Full Text PDF

Keloid, hypertrophic scars and basal cell carcinoma (BCC) falls under the category of non-melanoma skin cancer. Intralesional steroids, external beam radiation therapy, 5-Fluorouracil, cryotherapy, laser, etc are the available treatment options. However, recurrence has been reported with each type of treatment mode.

View Article and Find Full Text PDF

Introduction: Receptors on breast cancer cells play a crucial role in the management of patients. Trastuzumab is a widely used drug for the treatment of HER2/neu expressing tumors. ImmunoPET with trastuzumab is not feasible due to slow pharmacokinetics.

View Article and Find Full Text PDF

Objective: Selective intra-arterial radionuclide therapy (SIRT) using radiolabelled microspheres is for the delivery of therapeutic radioisotope to liver cancers and thus, sparing healthy liver. Several radiolabelled microspheres are commercially available. The main issue associated with these microspheres is affordability.

View Article and Find Full Text PDF

Rhenium-188 (Re) is a β, γ emitter and considered a theranostic radionuclide. It is used for bone pain palliation, treatment of unresectable hepatocellular carcinoma, skin keloids, etc. Re perrhenate is eluted from a W/Re generator in large volumes (8-14 ml) of 0.

View Article and Find Full Text PDF

Keloids are developed as fibrotic scar at the site of surgery or trauma and often enlarge beyond the original scar margins. Re-188 colloid coated customized patch was superficially fixed onto the lesion for 3 hrs. The same patch was reapplied on the lesion on third day for 3 hrs.

View Article and Find Full Text PDF